Pharmaceuticals, Biotechnology and Life Sciences
The Phase I study of Celltrion’s COVID-19 antiviral antibody treatment candidate in healthy volunteers is set for completion by Q3…
The Phase I study of Celltrion’s COVID-19 antiviral antibody treatment candidate in healthy volunteers is set for completion by Q3…
NEW YORK–(BUSINESS WIRE)–#Euronext–Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to…
NEW YORK–(BUSINESS WIRE)–#Euronext–Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to…
NEW YORK–(BUSINESS WIRE)–#Euronext–Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focusing on the development of novel therapeutics to…
– Demonstrates Evidence of Production of Antibodies and T Cell Responses in Mice: Shows Strong Antibody Responses, Activation of Sustainable…
– Demonstrates Evidence of Production of Antibodies and T Cell Responses in Mice: Shows Strong Antibody Responses, Activation of Sustainable…
– Demonstrates Evidence of Production of Antibodies and T Cell Responses in Mice: Shows Strong Antibody Responses, Activation of Sustainable…
ABU DHABI, United Arab Emirates–(BUSINESS WIRE)–The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to…
Awarded 1 Million € in non-dilutive Deep Tech funding, an initiative which supports advanced biotechnologies that are highly differentiated with…